1. Debates and Dilemmas, Part 1

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. Data that we discuss should be considered preliminary until published in a peer-reviewed journal.

4. Treatment Algorithm

5. Case 1: PD-L1 Negative

6. KEYNOTE-189: Efficacy

7. IMpower150: Efficacy and Safety

8. IMpower150: EGFR or ALK Mutations

9. Toxicity With Combination Immunotherapy

10. Tumor Mutational Burden

11. CheckMate 227: Efficacy

12. CheckMate 227: PD-L1 Subgroups and Safety

13. Case 1 (cont) Treatment of Choice

14. KEYNOTE-407 Efficacy in Taxane-Based Subgroups

15. KEYNOTE-407 Efficacy in ITT Population and PD-L1 Subgroups

16. Challenges With Patients at Risk for Immune-Related Toxicities

17. Case 1 (cont)

18. Evaluation and Diagnosis

19. Case 1 (cont)

20. Grading Pneumonitis

21. Management of Grade 1/2 Pneumonitis

22. Management of Grade 3/4 Pneumonitis

23. Case 2: PD-L1 Positive

24. KEYNOTE-024: Efficacy and Safety

25. KEYNOTE-042: Efficacy and Safety

26. KEYNOTE-407: Efficacy and Safety

27. Case 2 (cont) Treatment of Choice

28. Rationale for Treatment With Pembro Plus Chemo in PD-L1 ≥ 50% Population

29. Case 2 (cont)

30. Diagnostic Workup

31. Case 2 (cont)

32. Grading Hepatitis

33. Management of Grade 1/2 Hepatitis

34. Management of Grade 3/4 Hepatitis

35. Management of irAEs

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)

39. Abbreviations (cont)